Bilirubin Blood Test Market Report 2026

Bilirubin Blood Test Market Overview

• Bilirubin Blood Test market size has reached to $1.46 billion in 2025 • Expected to grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Rising Incidences Of Liver Diseases Driving Growth In The Bilirubin Blood Test Market • Market Trend: Strategic Partnerships Driving Expansion And Service Enhancement In The Bilirubin Blood Test Sector • North America was the largest region in 2025.

What Is Covered Under Bilirubin Blood Test Market?

The bilirubin blood test refers to a diagnostic procedure used to measure the levels of bilirubin in the blood. This test helps in assessing liver function and diagnosing conditions such as jaundice and liver disease. It is essential for evaluating bilirubin metabolism and detecting abnormalities related to liver health. The main types of bilirubin blood tests are the total serum bilirubin test, the indirect or unconjugated bilirubin test, and the direct or conjugated bilirubin test. The total serum bilirubin test measures the total amount of bilirubin in the blood, including both unconjugated (indirect) and conjugated (direct) bilirubin, which is crucial for evaluating overall liver health and helps in diagnosing various liver-related disorders. The age groups include adults, pediatrics, and infants, and the applications are hospital, clinic, and others.

What Is The Bilirubin Blood Test Market Growth Forecast?

The bilirubin blood test market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing burden of chronic liver disease and hepatitis, rising demand for early liver health assessment, increasing utilization of bilirubin testing in primary care settings, higher testing rates in aging and at-risk patient populations, expansion of point-of-care and specialty liver diagnostics. Major trends in the forecast period include increasing use of bilirubin testing for liver function assessment, growing adoption of bilirubin tests in neonatal jaundice screening, rising testing demand in hematology and preliver disorder evaluation, expansion of bilirubin monitoring across hospital and clinical settings, focus on early detection and routine screening for liver health.

Global Bilirubin Blood Test Market Segmentation

1) By Test Type: Total Serum Bilirubin Test, Indirect Or Unconjugated Bilirubin Test, Direct Or Conjugated Bilirubin Test 2) By Age Group: Adults, Pediatrics, Infants 3) By Application: Hospital, Clinic, Other Applications Subsegments: 1) By Total Serum Bilirubin Test: Routine Screening, Liver Function Assessment, Newborn Jaundice Detection 2) By Indirect Or Unconjugated Bilirubin Test: Hemolytic Anemia Diagnosis, Gilbert's Syndrome Detection, Monitoring For Preliver Conditions 3) By Direct Or Conjugated Bilirubin Test: Bile Duct Obstruction Diagnosis, Hepatitis And Liver Disease Monitoring, Post-Liver Condition Assessment

What Is The Driver Of The Bilirubin Blood Test Market?

The growing incidences of liver diseases are expected to propel the growth of the bilirubin blood test market going forward. Liver diseases refer to a range of conditions that impair the liver's ability to function properly, which can result from various causes such as infections, alcohol abuse, or metabolic disorders. The increasing number of liver disease cases can be attributed to rising rates of obesity, excessive alcohol consumption, viral infections, and unhealthy lifestyle choices, which collectively contribute to liver dysfunction and damage. Liver disease can significantly impact bilirubin levels in the body, and bilirubin blood tests help diagnose and monitor liver function, providing crucial insights into the health of patients while aiding healthcare providers in managing and treating liver-related conditions effectively. For instance, in April 2023, according to GOV.UK, a UK-based department for science, innovation, and technology, hospital admission rates for liver disease increased from 150.6 (148.2–152.9) to 155.2 (152.9–157.5) per 100,000 population between the financial years ending 2022 and 2023, underscoring a continued upward trend in liver disease-related hospitalizations. Therefore, growing incidences of liver diseases are driving the bilirubin blood test industry.

Key Players In The Global Bilirubin Blood Test Market

Major companies operating in the bilirubin blood test market are Abbott Laboratories, Thermo Fisher Scientific, F. Hoffmann‑La Roche Ltd, Siemens Healthineers, Danaher Corporation, Sysmex Corporation, Bio‑Rad Laboratories Inc, Ortho Clinical Diagnostics Inc, Mindray Medical International Limited, Randox Laboratories Ltd, bioMérieux SA, DiaSorin S.p.A, Horiba Ltd, ELITech Group SAS, Erba Mannheim, Hitachi High‑Technologies, DIRUI Industrial Co Ltd, Agappe Diagnostics, Awareness Technology Inc, Sekisui Diagnostics

Global Bilirubin Blood Test Market Trends and Insights

Major companies operating in the bilirubin blood test market are adopting a strategic partnership approach to expand their reach and enhance their service offerings. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in December 2023, Calmark Sweden AB, an Israel-based medical diagnostic biotechnology solutions company, signed an exclusive distributor agreement with Techno Orbits in Saudi Arabia for Calmark's bilirubin test designed for newborns. Techno Orbits will handle the distribution and sales of the product, leveraging its existing network and relationships, including with the Ministry of Health. This partnership aims to facilitate the introduction of Calmark’s bilirubin test into the Saudi market, where regulatory registration is expected to take 3 to 6 months.

What Are Latest Mergers And Acquisitions In The Bilirubin Blood Test Market?

In December 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a China-based medical technology provider, acquired a 75% stake in DiaSys Diagnostic Systems GmbH for an undisclosed amount. The acquisition aims to enhance Mindray's global competitive edge in the IVD sector by leveraging DiaSys's established supply chains and expertise in clinical chemistry. This move is expected to facilitate the expansion of Mindray's offerings in medium- to large-volume customer segments and improve service delivery. DiaSys Diagnostic Systems GmbH is a Germany-based diagnostic system provider offering bilirubin blood tests for liver disease.

Regional Outlook

North America was the largest region in the bilirubin blood test market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Bilirubin Blood Test Market?

The bilirubin blood test market consists of sales of products such as diagnostic devices for measuring bilirubin levels, including test kits, blood analyzers, and automated testing systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.